Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

204.15 -5.35 (-2.55%)
Streaming Delayed Price Updated: 12:09 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Analyzing Natera's Unusual Options Activity ↗
On Wednesday, shares of Natera (NASDAQ:NTRA) saw unusual o... 
Via Benzinga
News headline image
What Does Natera's Debt Look Like? ↗
Over the past three months, shares of Natera (NASDAQ:NTRA) moved higher by 10.31%. Before we understand the importance of debt, let us look at how much debt Natera has.... 
Via Benzinga
News headline image
7 Stocks to Buy in November in Light of Their October Dip ↗
October was a good month in the markets. It won't be easy to find stocks to buy on the dip. However, here are seven that will do the trick. 
Via InvestorPlace
News headline image
Medicare Coverage For Natera's Signatera For Pan-Cancer Immunotherapy Monitoring ↗
CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using Natera Inc... 
Via Benzinga
News headline image
Natera Raises FY21 Sales Outlook After Mixed Q3 earnings ↗
Natera Inc (NASDAQ: NTRA) posted Q3 sales of $158.1 million, +61% Y/Y, beating the consensus of $151.36 million, driven by an increase in test volume and product... 
Via Benzinga
News headline image
Natera Inc (NTRA) Q3 2021 Earnings Call Transcript ↗
NTRA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
CEO And President Of Natera Trades $2.4M In Company Stock ↗
Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on October 5, according to a new SEC filing. What Happened: A Form 4... 
Via Benzinga
Topics Regulatory Compliance
Expert Ratings For Natera ↗
Within the last quarter, Natera (NASDAQ:NTRA) has observe... 
Via Benzinga
Analyst Ratings For Natera ↗
Within the last quarter, Natera (NASDAQ:NTRA) has observed... 
Via Benzinga
News headline image
Expert Ratings for Natera ↗
Analysts have provided the following ratings for Natera (NASDAQ:NTRA) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 1 0 0... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
News headline image
Notable Natera Insider Trades $3M In Company Stock ↗
Burkes Michael Brophy, Chief Financial Officer at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 28, according to a new SEC filing. What Happened:... 
Via Benzinga
Topics Regulatory Compliance
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
CEO And President Of Natera Trades $3.41 Million In Company Stock ↗
Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 24, according to a new SEC filing. What Happened: A... 
Via Benzinga
Topics Regulatory Compliance
News headline image
Return on Capital Employed Overview: Natera ↗
After pulling data from Benzinga Pro it seems like during Q2, Natera (NASDAQ:NTRA) brought in sales totaling $142.03 million. However, earnings decreased 82.96%, resulting in a... 
Via Benzinga
News headline image
Natera Q2 Sales Tops Street Estimates On Higher Volumes, Raises FY21 Sales Outlook ↗
Natera Inc's (NASDAQ: NTRA) second-quarter revenues jumped 64% Y/Y $142 million, driven by an increase in test volume and product revenues, sharply ahead of the consensus... 
Via Benzinga
News headline image
3 Stocks Insiders Are Buying ↗
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
News headline image
Natera Sees Deeper Operating Losses In Q2 On Higher Commercialization Costs For New Product Offerings ↗
Natera Inc (NASDAQ: NTRA) expects 2Q'21 revenues of approximately $138 million to $141 million, equivalent to around 60% Y/Y growth. The Company's revenue... 
Via Benzinga
News headline image
This Explosive Biotech Is Taking On a Huge New Market ↗
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space. 
Via The Motley Fool
News headline image
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
News headline image
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
SVB Leerink raised Natera, Inc. (NASDAQ:NTRA) pr... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 ↗
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
News headline image
Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera
From Foundation Medicine
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021 ↗
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to... 
Via Benzinga
News headline image
Exact Sciences' First-Quarter Results Show Its Strength Under Pressure ↗
Despite ongoing pandemic-related headwinds, the medical diagnostic test maker's revenue grew. So how will it perform as those headwinds dissipate? 
Via The Motley Fool
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.